Literature DB >> 25750183

Low-molecular-weight adiponectin is more closely associated with disease activity of rheumatoid arthritis than other adiponectin multimeric forms.

Ping Li1, Li Yang, Cui-Li Ma, Bo Liu, Xin Zhang, Rui Ding, Li-qi Bi.   

Abstract

Adiponectin is divided into high-molecular-weight (HMW), medium-molecular-weight (MMW), and low-molecular-weight (LMW) forms. These forms differ not only in the number of adiponectin molecules but also in their biological activity. There are conflicting findings regarding the role of adiponectin in rheumatoid arthritis (RA). Moreover, few reports have described the relationships between serum adiponectin multimers levels and RA. Therefore, we examined the association of total adiponectin and its multimers with RA. Two study groups were examined: 180 recently diagnosed untreated RA patients with disease duration less than 1 year (RA group) and 160 age- and sex-matched control subjects (control group). RA-related factors, blood pressure, body mass index, glucose, complete lipid profile, and adiponectin multimers were measured. The levels of total adiponectin and each multimer of adiponectin were significantly lower in the RA than in the control (P < 0.01). Serum levels of total, HMW, MMW, and LMW were positively correlated with triglycerides levels and negatively correlated with the Disease Activity Score for 28 joints (DAS28). Multivariate regression analysis showed that total, HMW, and MMW adiponectin were independently associated with serum triglycerides level. LMW adiponectin was independently correlated with serum triglycerides level and DAS28. The decreased LMW adiponectin levels may be associated with disease activity of RA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25750183     DOI: 10.1007/s10067-015-2899-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  32 in total

1.  No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis.

Authors:  P Härle; P Sarzi-Puttini; M Cutolo; R H Straub
Journal:  Ann Rheum Dis       Date:  2006-07       Impact factor: 19.103

2.  Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis.

Authors:  Takao Nagashima; Hikaru Okubo-Fornbacher; Yoko Aoki; Yasuyuki Kamata; Hirotaka Kimura; Takeshi Kamimura; Hiroyuki Nara; Masahiro Iwamoto; Taku Yoshio; Hitoaki Okazaki; Seiji Minota
Journal:  J Rheumatol       Date:  2008-05       Impact factor: 4.666

3.  Serum adipokine levels in rheumatoid arthritis patients and their contributions to the resistance to treatment.

Authors:  Kyoung Soo Kim; Hyun-Mi Choi; Hye-In Ji; Ran Song; Hyung-In Yang; Soo-Kon Lee; Myung Chul Yoo; Yong-Beom Park
Journal:  Mol Med Rep       Date:  2013-10-29       Impact factor: 2.952

4.  Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin.

Authors:  Yoshimasa Aso; Ruriko Yamamoto; Sadao Wakabayashi; Toshihiko Uchida; Kan Takayanagi; Kohzo Takebayashi; Takehiko Okuno; Teruo Inoue; Koichi Node; Takashi Tobe; Toshihiko Inukai; Yasuko Nakano
Journal:  Diabetes       Date:  2006-07       Impact factor: 9.461

Review 5.  Clinical use of adiponectin as a marker of metabolic dysregulation.

Authors:  Kieren J Mather; Ronald B Goldberg
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-07-22       Impact factor: 4.690

6.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

7.  Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naive compared with patients with osteoarthritis and controls.

Authors:  Trine Bay Laurberg; Jan Frystyk; Torkell Ellingsen; Ib T Hansen; Anette Jørgensen; Ulrik Tarp; Merete Lund Hetland; Kim Hørslev-Petersen; Nete Hornung; Jørgen Hjelm Poulsen; Allan Flyvbjerg; Kristian Stengaard-Pedersen
Journal:  J Rheumatol       Date:  2009-08-14       Impact factor: 4.666

8.  Adiponectin gene variants, adiponectin isoforms and cardiometabolic risk in type 2 diabetic patients.

Authors:  Lydia Foucan; Suliya Maimaitiming; Laurent Larifla; Segho Hedreville; Jacqueline Deloumeaux; Marie-Odile Joannes; Anne Blanchet-Deverly; Fritz-Line Velayoudom-Céphise; Roberte Aubert; Roger Salamon; Jean-Paul Donnet; Frederic Fumeron
Journal:  J Diabetes Investig       Date:  2013-09-02       Impact factor: 4.232

9.  C-reactive protein, high-molecular-weight adiponectin and development of metabolic syndrome in the Japanese general population: a longitudinal cohort study.

Authors:  Yoshifumi Saisho; Hiroshi Hirose; Rachel Roberts; Takayuki Abe; Hiroshi Kawabe; Hiroshi Itoh
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

Review 10.  Role of adiponectin in metabolic and cardiovascular disease.

Authors:  Sewon Lee; Hyo-Bum Kwak
Journal:  J Exerc Rehabil       Date:  2014-04-30
View more
  9 in total

Review 1.  Adiponectin: a therapeutic target in the antiphospholipid syndrome?

Authors:  Mirjana B Bećarević; Božana S Nikolić; Svetlana D Ignjatović
Journal:  Rheumatol Int       Date:  2019-06-18       Impact factor: 2.631

2.  Adiponectin Is a Component of the Inflammatory Cascade in Rheumatoid Arthritis.

Authors:  Małgorzata Łączna; Patrycja Kopytko; Marta Tkacz; Katarzyna Zgutka; Michał Czerewaty; Maciej Tarnowski; Dariusz Larysz; Rafał Tkacz; Daniel Kotrych; Katarzyna Piotrowska; Krzysztof Safranow; Karolina Łuczkowska; Bogusław Machaliński; Andrzej Pawlik
Journal:  J Clin Med       Date:  2022-05-12       Impact factor: 4.964

3.  Serum adiponectin as a predictor of laboratory response to anti-TNF-α therapy in rheumatoid arthritis.

Authors:  Dorota Sikorska; Rafał Rutkowski; Joanna Łuczak; Włodzimierz Samborski; Janusz Witowski
Journal:  Cent Eur J Immunol       Date:  2018-10-30       Impact factor: 2.085

4.  Adiponectin is negatively associated with disease activity and Sharp score in treatment-naïve Han Chinese rheumatoid arthritis patients.

Authors:  Xixi Chen; Kaiwen Wang; Tao Lu; Jiajia Wang; Ting Zhou; Juan Tian; Bin Zhou; Li Long; Qiao Zhou
Journal:  Sci Rep       Date:  2022-02-08       Impact factor: 4.379

5.  No Causal Association Between Adiponectin and the Risk of Rheumatoid Arthritis: A Mendelian Randomization Study.

Authors:  Hanzhu Chen; Shuai Mi; Jiahao Zhu; Weidong Jin; Yasong Li; Tianle Wang; Yingjun Li; Chunhong Fan
Journal:  Front Genet       Date:  2021-09-24       Impact factor: 4.599

6.  Low Molecular Weight Adiponectin Increases the Mortality Risk in Very Old Patients.

Authors:  Stefano Rizza; Marina Cardellini; Alessio Farcomeni; Pasquale Morabito; Daniele Romanello; Giovanni Di Cola; Maria Paola Canale; Massimo Federici
Journal:  Aging Dis       Date:  2018-10-01       Impact factor: 6.745

7.  Middle- and high-molecular weight adiponectin levels in relation to nonalcoholic fatty liver disease.

Authors:  Kun Lian; Yu-Nan Feng; Rong Li; Hao-Lin Liu; Peng Han; Lei Zhou; Cheng-Xiang Li; Qin Wang
Journal:  J Clin Lab Anal       Date:  2019-12-27       Impact factor: 2.352

Review 8.  Role of Adiponectin in the Pathogenesis of Rheumatoid Arthritis.

Authors:  Kamila Szumilas; Paweł Szumilas; Sylwia Słuczanowska-Głąbowska; Katarzyna Zgutka; Andrzej Pawlik
Journal:  Int J Mol Sci       Date:  2020-11-04       Impact factor: 5.923

9.  Re-evaluation of serum leptin and adiponectin concentrations normalized by body fat mass in patients with rheumatoid arthritis.

Authors:  Kazuhisa Chihara; Naoki Hattori; Norihiro Ichikawa; Takeshi Matsuda; Takanori Saito
Journal:  Sci Rep       Date:  2020-09-28       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.